S-EPMC11694292 - Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma - OmicsDI

Unknown

Dataset Information

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma

ABSTRACT:

SUBMITTER:

PROVIDER: S-EPMC11694292 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature